MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Intermediaries
Private Equity, Investment Banking, Financial Services, Factoring
Analysts, Investment Banks: Top Performing Recommendations & Analysis
Finance & Acquisitions: BAKER BROTHERS ADVISORS LP
Argenx SE (NASDAQ: ARGX)*
Organization & Developments: Argenx
Parents
Argenx SE (NASDAQ: ARGX)*
Children
*ArGen-X has offices in Belgium and The Netherlands
*Developer of human monoclonal antibodies
*Flagship therapy, efgartigimod, developed using proprietary ABDEG technology, shows promise in treating autoimmune disorders
*NETHERLANDS-BASED BIOTECHNOLOGY COMPANY DEVELOPS THERAPIES TO TREAT SEVERE AUTOIMMUNE DISEASES AND CANCER.
2014: arGEN X Inks Long Term Alliance With Shire
2017: Argenx: This ASH Winner Has Further Upside Ahead - Argenx SE (NASDAQ:ARGX)
2018: Argenx: This Below-Radar Dutch Company Is A Potential Winner_seekingalpha.com
2020: Argenx: Competitive Positioning In The GMG Space
2020: Argenx's autoimmune phase 3 hits goals, teeing up FDA filing
2022: argenx: Vyvgart Continues To Perform Well, Key Pipeline Catalyst Next Quarter_ seekingalpha.com
2023: argenx: Back To Earth After 2 Clinical Trial Failures_seekingalpha.com
2023: argenx: Efgartigimod Is Not Just A Drug, A Cornerstone
2024: Argenx posts J&J-rivaling Sjögren's data, massively upscales Vyvgart patient population at R&D day
2024: argenx: Myositis Data Could Add Billions In Value
2024: Argenx: Strong CIDP Launch, But gMG Growth Propels Q3 Sales Beat (NASDAQ:ARGX)_ seekingalpha.com
2024: argenx: Upgrading To 'Strong Buy' On Vyvgart's Q4 Sales, Empasiprubart Data, Pipeline Expansion
2024: Halozyme Therapeutics, Argenx Expand Global Collaboration & License Agreement
2025: argenx: Lofty Valuation Diminishes Appeal Amid Autoimmune Expansion (Rating Downgrade)
Jumps
*Key People: Argenx
Finance & Acquisitions: Argenx